Who Owns CompuGroup Medical Company?

Who Owns CompuGroup Medical?

In a significant development for the European e-health sector, CompuGroup Medical SE & Co. KGaA, a global leader in healthcare software, recently announced a strategic partnership with CVC Capital Partners in December 2024, followed by a public delisting offer in May 2025. This pivotal event underscores the dynamic nature of corporate ownership and its profound impact on a company's strategic direction, market influence, and accountability to its stakeholders. Founded in 1987 by Frank Gotthardt and headquartered in Koblenz, Germany, CompuGroup Medical (CGM) has grown from its origins as Compudent AG to become a cornerstone of digital healthcare, driven by its founder's vision to streamline medical processes through intelligent IT solutions.

CompuGroup Medical specializes in developing and providing comprehensive software and communication solutions for the healthcare sector, including practice management systems, electronic health records, and tailored solutions for pharmacies, laboratories, and hospitals. With over 8,700 employees across 19 countries and products distributed in 60 countries worldwide as of 2024, CGM serves over 1.6 million professional users, solidifying its market leadership, particularly in the German outpatient sector. The company reported revenues of EUR 1.154 billion for the financial year 2024, with recurring revenues making up 74% of the total, demonstrating a robust and stable business model.

Understanding CompuGroup Medical ownership is key to grasping its strategic trajectory. Initially, the company was primarily owned by its founder, Frank Gotthardt, who established the firm in 1987. Over the years, as CGM grew and eventually went public, its CompuGroup Medical shareholders evolved to include a mix of institutional investors and the public market. The recent strategic partnership with CVC Capital Partners in December 2024 and the subsequent public delisting offer in May 2025 mark a significant shift in its CGM ownership structure, moving towards a more concentrated private equity influence. This transition impacts the CompuGroup Medical investors and the broader CompuGroup Medical company structure.

The journey of CompuGroup Medical SE reflects a common pattern in the technology and healthcare sectors, where founder-led innovation transitions through various ownership phases. As a publicly traded entity, CompuGroup Medical stock ownership was distributed among numerous shareholders. However, the move towards delisting suggests a change in its CompuGroup Medical company ownership details, potentially offering more flexibility for strategic initiatives and long-term investments away from the quarterly pressures of public markets. This evolution is crucial for anyone tracking CompuGroup Medical investors or seeking to understand its CompuGroup Medical acquisition history ownership and CompuGroup Medical ownership changes.

The CompuGroup Medical board of directors ownership and the founder's continued influence, even after potential shifts in majority ownership, are vital aspects to consider. For those interested in the specifics of CompuGroup Medical beneficial ownership, tracking the filings related to the CVC Capital Partners transaction will provide clarity on the new CompuGroup Medical majority owner and its stake. This dynamic landscape means that understanding who owns CompuGroup Medical requires ongoing attention to corporate announcements and regulatory filings, especially concerning its CompuGroup Medical investor relations.

The company's commitment to innovation is evident in its product offerings, such as the CompuGroup Medical BCG Matrix, which helps analyze its diverse portfolio. The question of; Is CompuGroup Medical publicly traded; has a recent answer with the delisting process. For those asking; Who are the major shareholders of CompuGroup Medical?; the answer is evolving with the CVC Capital Partners involvement. The overall CompuGroup Medical ownership percentage held by various entities is a key indicator of its governance and strategic direction.

CompuGroup Medical SE & Co. KGaA, initially established as Compudent GmbH in 1987, underwent a significant transformation in its early ownership structure. The pivotal moment arrived in 1992 when Frank Gotthardt, a computer scientist, acquired all ordinary shares of Compudent AG. He then merged it with his own company, 'Gotthardt Computer GmbH,' based in Koblenz. This strategic consolidation led to the retention of the Compudent AG name, a testament to its existing market presence, with Frank Gotthardt emerging as the sole founder and principal driving force behind the unified entity.

Gotthardt's foundational vision centered on leveraging software to alleviate the administrative burdens faced by medical professionals, thereby enabling them to dedicate more time to patient care. While specific details regarding initial equity distribution or the involvement of other early investors beyond Gotthardt's acquisition are not extensively documented publicly, his decisive takeover in 1992 marked a crucial period of consolidated control under his leadership. The company's evolution continued with its renaming to Compugroup Holding AG in 1997, signaling its expanding operational scope. Frank Gotthardt's background in computer science, complemented by his prior experience developing software for diverse sectors, including the meat industry, provided the essential technical expertise and entrepreneurial drive for CompuGroup Medical's inception and subsequent early growth.

Founding Year

CompuGroup Medical was founded in 1987, initially operating under the name Compudent GmbH.

Key Acquisition

In 1992, Frank Gotthardt acquired all ordinary shares of Compudent AG, consolidating ownership.

Merger and Name Retention

Compudent AG was merged with Gotthardt Computer GmbH, retaining the Compudent AG name due to its market position.

Founder's Vision

Frank Gotthardt envisioned using software to reduce administrative tasks for medical professionals.

Company Renaming

The company was renamed Compugroup Holding AG in 1997, reflecting its expanding business activities.

Founder's Background

Frank Gotthardt's expertise in computer science and prior software development experience were foundational.

Frank Gotthardt's early leadership and strategic acquisition in 1992 laid the groundwork for CompuGroup Medical's future growth and market presence. His commitment to improving healthcare efficiency through technology has been a consistent theme throughout the company's development, influencing its product strategy and its Target Market of CompuGroup Medical. While the specifics of early CompuGroup Medical investors are not widely publicized, Gotthardt's singular acquisition of Compudent AG in 1992 firmly established his control and vision for the company's trajectory.

Early Ownership Dynamics

Frank Gotthardt's acquisition of Compudent AG in 1992 consolidated ownership under his direct control.

• Frank Gotthardt is recognized as the sole founder.
• The merger in 1992 was a key event in establishing unified ownership.
• Early investor details beyond Gotthardt are not publicly detailed.
• The company's initial name was Compudent GmbH.
• The company was later renamed Compugroup Holding AG in 1997.

Complete CompuGroup Medical Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

CompuGroup Medical's journey from a private company to a publicly traded entity began with its Initial Public Offering on February 14, 2000. This significant event broadened its investor base and altered its ownership dynamics. Recent developments in late 2024 and early 2025 have further reshaped this structure, notably through a strategic partnership with CVC Capital Partners.

The founding family, under the leadership of Frank Gotthardt, continues to hold a substantial influence over CompuGroup Medical's ownership. As of June 27, 2025, shareholders associated with the founding family collectively possess approximately 50.12% of the company's shares, maintaining a majority stake. Frank Gotthardt, through GT1 Vermögensverwaltung GmbH, remains the largest individual shareholder.

In December 2024, CVC Capital Partners initiated a voluntary public tender offer, proposing EUR 22.00 per share with the intention of delisting the company. This offer represented a premium of 51.1% over the average share price in the three months preceding December 6, 2024. By February 12, 2025, approximately 21.85% of shares had accepted this offer. Consequently, as of June 27, 2025, CVC Capital Partners holds a total stake of about 27.78% of the share capital and voting rights, positioning them as the second-largest shareholder. This collaboration with CVC aims to enhance CompuGroup Medical's financial flexibility and establish a long-term private ownership framework, while the Gotthardt family retains majority control. The free float, which stood at roughly 47.2% in May 2024, was expected to be delisted, with the last trading day scheduled for June 24, 2025.

Key Ownership Developments

CompuGroup Medical's ownership structure has seen significant shifts, particularly with the entry of a major private equity partner. The founding family continues to be the primary majority owner.

• Founding family holds 50.12% as of June 27, 2025.
• CVC Capital Partners acquired 27.78% by June 27, 2025.
• The company underwent a delisting process, with the last trading day on June 24, 2025.
• This move aims for greater financial flexibility and a private ownership structure.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

CompuGroup Medical SE & Co. KGaA operates with a distinct governance framework as a Kommanditgesellschaft auf Aktien (KGaA), a partnership limited by shares. This structure designates managing directors of the general partner, CompuGroup Medical Management SE, as the entities responsible for the company's overall leadership and operational management. The board composition reflects a blend of foundational family influence and new strategic partnerships.

Frank Gotthardt, the founder, holds a pivotal role as the Chairman of the Administrative Board. His son, Prof. (apl.) Dr. med. Daniel Gotthardt, assumed the position of Chief Executive Officer (CEO) on September 1, 2024, and also serves as a member of the Administrative Board, underscoring the family's continued strategic involvement. Daniela Hommel joined the executive team as Chief Financial Officer (CFO) on February 1, 2024. The management team also includes Emanuele Mugnani, Hannes Reichl, and Dr. Ulrich Thomé. Philipp von Ilberg chairs the Supervisory Board.

The company's ownership and voting power dynamics have seen significant shifts, particularly following the strategic partnership with CVC Capital Partners in December 2024 and the subsequent delisting offer in May 2025. Upon the completion of the delisting, CVC Capital Partners is slated to gain three seats on CompuGroup Medical's expanded Administrative Board, reflecting its substantial stake of approximately 27.78%. Despite this new partnership, the founding Gotthardt family is set to retain control, holding an estimated 50.12% of the shares. The general voting principle adheres to one-share-one-vote, though the KGaA structure inherently concentrates significant control with the general partner. The management and boards have expressed their support for the delisting offer, viewing it as a strategic move to foster long-term innovation and growth by removing the constraints associated with public listing pressures. This transition marks a notable chapter in the Brief History of CompuGroup Medical.

Key Ownership and Board Dynamics

The governance of CompuGroup Medical SE & Co. KGaA is shaped by its KGaA structure and recent strategic investments. The founding family maintains majority control, while new partners gain board representation.

• Founding family (Gotthardt) holds approximately 50.12% of shares.
• CVC Capital Partners will hold approximately 27.78% after delisting.
• CVC Capital Partners will have three seats on the Administrative Board.
• The KGaA structure grants significant control to the general partner.
• The delisting is viewed as beneficial for future innovation and growth.

CompuGroup Medical Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

The ownership landscape of CompuGroup Medical has seen significant shifts between 2024 and mid-2025, moving towards a more consolidated private structure. A pivotal development was the strategic alliance formed in December 2024 between the founding Gotthardt family and CVC Capital Partners. This partnership initiated a voluntary public tender offer by CVC for CompuGroup Medical shares at EUR 22.00 per share, followed by a public delisting offer in May 2025. The tender offer, which concluded on February 12, 2025, garnered acceptances for 21.85% of the shares. As of June 27, 2025, CVC had secured approximately 27.78% of the share capital and voting rights, positioning them as the second anchor shareholder alongside the Gotthardt family, who continue to hold a majority stake of approximately 50.12%. Consequently, the company was delisted from the regulated market of the Frankfurt Stock Exchange (Prime Standard) effective June 24, 2025. This transition aims to provide greater financial flexibility and support long-term innovation and growth strategies away from public market pressures.

In terms of leadership, Prof. (apl.) Dr. med. Daniel Gotthardt, son of the founder, took over as CEO on September 1, 2024, succeeding Michael Rauch. This succession maintains a strong family presence in the company's leadership. Financially, for the fiscal year 2024, CompuGroup Medical reported revenues of EUR 1.154 billion, a 3% decrease compared to the previous year, largely due to one-off effects from prior years. However, recurring revenues saw a 5% increase, reaching EUR 853.9 million, and now constitute 74% of total revenues. Adjusted EBITDA for 2024 was reported at EUR 224.6 million, marking a 15% decline. The company anticipates a return to growth in 2025.

Recent strategic moves include the acquisition of perimed Fachbuch Verlag Dr. med. Straube GmbH in April 2025, a medical publisher, aimed at bolstering patient information services. Additionally, Benedikt Brueckle was appointed as the new CEO of CompuGroup Medical US, effective January 1, 2025, succeeding Derek Pickell. These developments underscore a strategic focus on consolidation and core e-health solutions, supported by an updated ownership structure designed to foster long-term growth and innovation, particularly in areas such as AI-based solutions. Understanding these ownership changes is crucial for grasping the company's strategic direction, much like understanding its Marketing Strategy of CompuGroup Medical.

Leadership Transition

Prof. (apl.) Dr. med. Daniel Gotthardt assumed the CEO role on September 1, 2024. This succession ensures continued family influence at the highest level. The transition follows Michael Rauch's departure on August 31, 2024.

Financial Performance Highlights

For fiscal year 2024, revenues were EUR 1.154 billion, with recurring revenues up 5% to EUR 853.9 million. Adjusted EBITDA stood at EUR 224.6 million, a 15% decrease. The company anticipates a return to growth in 2025.

Strategic Acquisition

In April 2025, the company acquired perimed Fachbuch Verlag Dr. med. Straube GmbH. This medical publisher acquisition aims to enhance patient information offerings. It aligns with the strategy to strengthen core e-health solutions.

Ownership Restructuring

A partnership with CVC Capital Partners led to a delisting from the Frankfurt Stock Exchange by June 24, 2025. CVC holds approximately 27.78% of shares, with the Gotthardt family retaining majority ownership. This shift supports long-term strategic goals.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE